Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.70 |
| ▸ | RAB9A | P51151 | 5/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.47 |
| ▸ | RELA | Q04206 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30063475 | 1.00 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2HDAC6KDM4E | |
| SCHEMBL381600 | 0.86 | SMN1; SMN2 (0.64) | NPC1RAB9ASMN1; SMN2KDM4ENFKB1 | |
| SCHEMBL1105986 | 0.82 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2KDM4ENFKB1 | |
| SCHEMBL2031602 | 0.81 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2HDAC6KDM4E | |
| SCHEMBL9307890 | 0.81 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2HDAC6KDM4E | |
| SCHEMBL6985206 | 0.81 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2HDAC6KDM4E | |
| SCHEMBL11147962 | 0.81 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2HDAC6KDM4E | |
| Hydrochloric Acid SCHEMBL11596610 | 0.81 | RAB9A (0.68) | NPC1RAB9ASMN1; SMN2HDAC6KDM4E | |
| SCHEMBL31398710 | 0.80 | HDAC1 (0.51) | NPC1RAB9ASMN1; SMN2HDAC6KDM4E | |
| SCHEMBL21708400 | 0.79 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2HDAC6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118302427-A | Fused ring derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20240150339-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2024-05-09 | — | — | US | disclosed |
| EP-4291557-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2023-12-20 | — | — | EP | disclosed |
| WO-2023098880-A1 | FUSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2023-06-08 | — | — | WO | disclosed |
| WO-2023098880-A1 | FUSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2023-06-08 | — | — | WO | disclosed |
| WO-2022172037-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150339-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE4B, PDE4C | NPC1 3795/4885RAB9A 1715/4885SMN1; SMN2 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.